Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma
Liying Ren,Dong Bo Chen,Xuanzhi Yan,Shaoping She,Yao Yang,Xue Zhang,Weijia Liao,Hongsong Chen
DOI: https://doi.org/10.2147/jhc.s423549
2024-11-29
Journal of Hepatocellular Carcinoma
Abstract:Liying Ren, 1, &ast Dong Bo Chen, 1, &ast Xuanzhi Yan, 2 Shaoping She, 1 Yao Yang, 1 Xue Zhang, 1 Weijia Liao, 2 Hongsong Chen 1 1 Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, 100044, People's Republic of China; 2 Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongsong Chen, Peking University People's Hospital, Peking University Hepatology Institute, No. 11 Xizhimen South Street, Beijing, 100044, People's Republic of China, Email Weijia Liao, Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, No. 15, Lequn Road, Xiufeng District, Guilin, Guangxi, 541001, People's Republic of China, Email Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the third leading cause of cancer-related deaths. Imaging plays a crucial role in the screening, diagnosis, and monitoring of HCC; however, the potential mechanism regarding phenotypes or molecular subtyping remains underexplored. Radiomics significantly expands the selection of features available by extracting quantitative features from imaging data. Radiogenomics bridges the gap between imaging and genetic/transcriptomic information by associating imaging features with critical genes and pathways, thereby providing biological annotations to these features. Despite challenges in interpreting these connections, assessing their universality, and considering the diversity in HCC etiology and genetic information across different populations, radiomics and radiogenomics offer new perspectives for precision treatment in HCC. This article provides an up-to-date summary of the advancements in radiomics and radiogenomics throughout the HCC care continuum, focusing on the clinical applications, advantages, and limitations of current techniques and offering prospects. Future research should aim to overcome these challenges to improve the prognosis of HCC patients and leverage imaging information for patient benefit. Keywords: hepatocellular carcinoma, radiomics, radiogenomics Hepatocellular carcinoma (HCC) is a leading global cancer and cause of death. 1,2 It often results from viral hepatitis, 3,4 alcohol use, non-alcoholic fatty liver disease (NAFLD), and cirrhosis. 5,6 Early-stage HCC is treated with surgery or transplantation, but most cases are diagnosed late, requiring transcatheter arterial chemoembolization (TACE) and ablation. 7 Combining immune checkpoint inhibitors with anti-angiogenic drugs has improved survival. 8 Imaging is essential in managing HCC patients, including screening, diagnosis, treatment, and prognosis. 9,10 Ultrasonography facilitates early detection of hepatic lesions. Combined with color Doppler imaging and serum alpha-fetoprotein levels, it aids in characterizing HCC. 11 Dynamic contrast-enhanced CT and multiparametric MRI are useful for diagnosis, 12 while 1 8 F-FDG PET/CT monitors systemic metastasis. 13 Imaging guides non-surgical treatments like local ablation, and TACE requires angiography. RECIST criteria rely on imaging. 14 Despite advancements, HCC survival rates remain low, with a high postoperative recurrence rate (70% within five years), primarily early recurrence (within two years). 7 This issue arises from complex molecular mechanisms and HCC's immune microenvironment. 15 Current imaging provides visual data but lacks precise guidance for personalized treatment and prognosis due to limited incorporation of molecular and microenvironmental information. Research has shown that medical imaging data contains valuable information on tumor heterogeneity, extractable through artificial intelligence (AI) methods. 16 Recent HCC research highlights semantic features in radiomics, bridging quantitative imaging and clinical interpretations. These features, like tumor shape and texture, enhance analysis by providing nuanced insights into tumor heterogeneity. 17,18 As shown in Figure 1, since the advent of Sanger sequencing, 19,20 it has developed over several decades to achieve single-cell resolution. In recent years, spatial transcriptomics has enabled the acquisition of spatial distribution information of different cel -Abstract Truncated-
oncology